Acute lymphoblastic leukemia in adolescents and young adults

Acta Haematologica

Volumn 132, Issue 3-4, 2014, Pages 264-273

  Burke, Patrick W ^a   Douer, Dan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute lymphoblastic leukemia age stratification; Acute lymphoblastic leukemia molecular diversity; Asparaginase; Pediatrics inspired treatment

Indexed keywords

ANTHRACYCLINE; ANTIBODY; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CELL THERAPY; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); EVENT FREE SURVIVAL; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SURVIVAL RATE; YOUNG ADULT; AGE; BIOLOGICAL THERAPY; REVIEW;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; SURVIVAL RATE;

EID: 84908620920     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000360204     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jema A: Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
2. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
3. Larson RA, Dodge RK, Burns CP, Lee EL, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD, Schiffer CA: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood 1995; 85: 2025-2037.
4. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RA: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B Study 19802. Cancer 2013; 119: 90-98.
5. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.
6. Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2464-2471.
7. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ: Results of treatment with hyper-CVAD, a dose intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
8. Pulte D, Gondos A, Brenner H: Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009; 113: 1408-1411.
9. Douer D: Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Practice Res Clin Haematol 2008; 21: 647-658.
10. Harrison CJ: Cytogenetics of pediatric and adolescent acute lymphoblastic leukemia. Br J Haematol 2009; 144: 147-156.
11. Hunger SP, Schafer ES: Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol 2011; 8: 417-424.
12. Wood WA, Lee SJ: Malignant hematologic diseases in adolescents and young adults. Blood 2011; 117: 5803-5815.
13. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, Deangelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM: Acute lymphoblastic leukemia. J Natl Compr Canc Netw 2012; 10: 858-914.
14. Hoelzer D, Thiel E, Loffler H, Büchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Ruhl H, Maschmeyer H, Lipp T, Nowrousian MR, Burkert M, Gerecke D, Pralle H, Müller U, Lunsken CH, Fülle H, Ho AD, Küchler R, Busch FW, Schneider W, Görg CH, Emmerich B, Braumann D, Vaupel HA, von Paleske A, Bartels A, Neiss A, Messerer D: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-131.
15. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189-3197.
16. Mulligan CG: Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest 2012; 122: 3407-3415.
17. Paulsson K, Cazier JB, Macdougall F, Stevens J, Stasevich I, Vrcelj N, Chaplin T, Lillington DM, Lister TA, Young BD: Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc Natl Acad Sci USA 2008; 105: 6708-6713.
18. Loh ML, Harvey RC, Mullighan CG, Linda SB, Devidas M, Borowitz MJ, Carroll AJ, Chen I-M, Gastier-Foster NM, Heerema NA, Kang H, Raetz EA, Roberts KG, Zhang J, Winick N, Wood BL, Larsen EC, Carroll WL, Willman CL, Hunger SP: A BCR-ABL1-like gene expression profile confers a poor prognosis in patients with high-risk acute lymphoblastic leukemia (HR-ALL): A report from Children's Oncology Group (COG) AALL0232. Blood 2011; 118: 743.
19. Stock W: Adolescents and young adults with acute lymphoblastic leukemia. Am Soc Hematol Educ Program 2010; 2010: 21-29.
20. Douer D: Adult lymphoblastic leukemia: A cancer with no standard of care. Acta Haematol 2013; 130: 196-198.
21. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007: 25: 813-819.
22. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, Mattano LA Jr, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel NL: Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: A report from the Children's Oncology Group. J Clin Oncol 2009; 27: 5189-5194.
23. Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Coustan-Smith E, Jeha S, Cheng C, Metzger ML, Bhojwani D, Inaba H, Raimondi SC, Onciu M, Howard SC, Leung W, Downing JR, Evans WE, Relling MV: Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2010; 29: 386-391.
24. Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, Seibel NL: Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: A report from the Children's Oncology Group. Blood 2011; 117: 3010-3015.
25. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J; Children's Cancer Group; Cancer and Leukemia Group B studies: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646-1654.
26. Schiffer CA: Differences in outcome in adolescents with acute lymphoblastic leukemia: A consequence of better regimens? Better doctors? Both? J Clin Oncol 2003; 21: 760-761.
27. Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, Kauppila M, Koistinen P, Parto K, Riikonen P, Salmi TT, Silvennoinen R, Elonen E, Saarinen-Pihkala UM: Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 2008; 93: 1161-1168.
28. Thomas DA, O'Brien S, Rytting M, Faderl S, Cortes J, Wierda WG, Ravandi F, Kantarjian HM: Acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) after frontline therapy with hyper-CVAD regimens. Blood 2008; 112: 1930.
29. Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A: Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel. Leuk Lymphoma 2011; 52: 2237-2253.
30. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AMJ, Periclou AP, Avramis VI: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109: 2744-2750.
31. Douer D, Aldoss I, Lunning MA, Ramezani L, Burke P, Mark L, Vrona J, Park JH, Tallman MS, Pullarkat V, Mohrbacher AM, Avramis VI: Pharmacokinetics-based modification of intravenous pegylated asparaginase dosing in the context of a ?pediatric-inspired' protocol in adults with newly diagnosed acute lymphoblastic leukemia (ALL). Synapse 2012; 120: 1495.
32. Burke PW, Aldoss I, Lunning MA, Avramis VI, Mohrbacher AM, Pullarkat V, Tallman MS, Douer D: High-grade pegylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles. Blood 2013; 122: 2671.
33. Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, Grande C, Heras I, Bethencourt C, Feliu E, Ortega JJ: Comparison of the results of the treatment of adolescents and young adults with standardrisk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008; 26: 1843-1849.
34. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Lafage-Pochitaloff M, Chassevent A, Lhéritier V, Macintyre E, Béné MC, Ifrah N, Dombret H: Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. J Clin Oncol 2009; 27: 911-918.
35. DeAngelo DJ, Dahlberg S, Silverman LB, Couban S, Amrein PC, Seftel MD, Turner AR, Leber B, Howsan-Jan K, Wadleigh M, Sirulnik LA, Supko J, Galinsky I, Sallan SE, Stone RM: A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 2007; 110: 587.
36. Goekbuget N, Beck J, Brueggemann M: PEGasparaginase intensification in adult acute lymphoblastic leukemia (ALL): Significant Improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for adult ALL (GMALL) Study 07/2003. Blood 2010: 116: 494.
37. Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KW, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM: Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 2009; 146: 76-85.
38. Douer D: What is the impact, present and future, of novel targeted agents in acute lymphoblastic leukemia? Best Pract Res Clin Hematol 2012; 25: 453-464.
39. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM: Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28: 3880-3889.
40. Brentjens RJ: CARs and cancers: Questions and answers. Blood 2012; 119: 3872-3873.
41. Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, Wattel MM, van Esser JW, Valk PJ, Cornelissen JJ: Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 2009; 23: 627-629.